Compounded Tirzepatide and 503A Compounding Pharmacies

The conversation around compounding pharmacies has gained heightened attention in the current landscape of medication shortages and evolving healthcare needs. The FDA’s recent, abrupt removal and subsequent reinstatement of access to compounded tirzepatide injections (GLP-1) underscores the essential role that 503a compounding pharmacies play in facilitating patient access to essential medications in shortage.